CATCH is an indication-specific diagnostic platform, which drives the implementation ofintegrative, genomic profiling for metastatic breast cancer into the clinics. The mainobjective of this approach is to identify biomarkers and drug targets to guide targetedtherapeutic interventions.Eligible are all metastatic breast cancer patients (independent of gender), irrespectiveof molecular subtype.At initial diagnosis of distant metastasis or progress at disease progression, biopsysamples from a prognostic-relevant metastasis are retrieved during standard-of-careprocedures for central analyses, together with blood samples. In parallel to allstandard-diagnostic measures, genomic and transcriptomic profiling is conducted to inferthe underlying biology of the disease and identify patients who might profit frombiomarker-guided interventions in clinical trials.Samples not required for standard-of-care clinical procedures or genomic profiling aresystematically collected in a dedicated bio-reposit
Die CATCH-Studie richtet sich an Patientinnen und Patienten mit einer Brustkrebserkrankung in einem fortgeschrittenen Stadium (metastasiert). Ziel ist es, weitere zielgerichtete Therapiemöglichkeiten, über das Standardverfahren hinaus, zu ermitteln, die auf die individuelle genetische Tumorbiologie abgestimmt sind.
